Ferrari N.V. (RACEN.MX)
| Previous close | 6,600.00 |
| Open | 0.00 |
| Bid | 6,600.00 x 500000 |
| Ask | 6,900.00 x 2000 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 378 |
| Market cap | 1.232T |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | 54.05 |
| EPS (TTM) | 122.10 |
| Earnings date | N/A |
| Forward dividend & yield | 45.10 (0.68%) |
| Ex-dividend date | 22 Apr 2024 |
| 1y target est | N/A |
ZacksAuto Roundup: KMX's Weak Quarterly Results, TSLA's FSD Price Cut & More
While CarMax's (KMX) fiscal fourth-quarter 2024 earnings and sales miss estimates, Tesla (TSLA) slashes the monthly subscription price of FSD software to half.
GlobeNewswireFerrari N.V.: Periodic Report on the Buyback Program
Maranello (Italy), April 15 2024 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 350 million share buyback program announced on November 7, 2023, as the fourth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Fourth Tranche”), the additional common shares - reported in aggregate form, on a dai
- Reuters
UPDATE 1-Agnellis' Exor targets growth in healthcare sector
Exor, the investment arm of the Agnelli family, has a growing interest in the healthcare industry, where it has already invested almost 4 billion euros ($4.3 billion), CEO John Elkann said on Thursday. "The increased cost of healthcare services combined with a shortage of medical staff is driving demand for innovative new approaches to tackle global health problems," he said in his annual letter to Exor shareholders. Exor views healthcare as a "long-term, structural growth sector," added Elkann, the scion of the Agnelli family and chair of automakers Stellantis and Ferrari.
